Allianz Asset Management
RPRX icon

Allianz Asset Management’s Royalty Pharma RPRX Stock Holding History

Allianz Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1M Buy
286,986
+162,080
+130% +$8.44M 0.01% 853
2026
Q1 		$5.99M Sell
124,906
-182,207
-59% -$7.98M 0.01% 1073
2025
Q4 		$11.9M Buy
307,113
+71,886
+31% +$2.74M 0.01% 792
2025
Q3 		$8.3M Sell
235,227
-127,319
-35% -$4.61M 0.01% 920
2025
Q2 		$13.1M Buy
362,546
+168,955
+87% +$5.6M 0.02% 719
2025
Q1 		$6.03M Sell
193,591
-356,968
-65% -$11.3M 0.01% 1010
2024
Q4 		$14M Sell
550,559
-208,864
-28% -$5.54M 0.02% 643
2024
Q3 		$21.5M Buy
759,423
+553,550
+269% +$15.3M 0.03% 522
2024
Q2 		$5.43M Buy
205,873
+57,870
+39% +$1.6M 0.01% 928
2024
Q1 		$4.49M Buy
148,003
+82,921
+127% +$2.44M 0.01% 909
2023
Q4 		$1.83M Sell
65,082
-53,802
-45% -$1.48M ﹤0.01% 1363
2023
Q3 		$3.23M Buy
118,884
+33,628
+39% +$999K 0.01% 1189
2023
Q2 		$2.62M Sell
85,256
-30,973
-27% -$1.05M ﹤0.01% 1159
2023
Q1 		$4.19M Sell
116,229
-17,092
-13% -$634K 0.01% 1045
2022
Q4 		$5.27M Buy
133,321
+9,648
+8% +$403K 0.01% 893
2022
Q3 		$4.97M Buy
123,673
+66,291
+116% +$2.83M 0.01% 886
2022
Q2 		$2.41M Buy
57,382
+33,977
+145% +$1.39M ﹤0.01% 1364
2022
Q1 		$911K Sell
23,405
-4,512
-16% -$177K ﹤0.01% 1889
2021
Q4 		$1.11M Buy
27,917
+11,032
+65% +$429K ﹤0.01% 1871
2021
Q3 		$610K Buy
16,885
+6,662
+65% +$259K ﹤0.01% 2143
2021
Q2 		$419K Buy
10,223
+5,260
+106% +$224K ﹤0.01% 2124
2021
Q1 		$216K Hold
4,963
– – ﹤0.01% 2113
2020
Q4 		$248K Buy
+4,963
New +$211K ﹤0.01% 1777

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allianz Asset Management's RPRX Position: Q2 2026 in Review

Allianz Asset Management increased its Royalty Pharma (RPRX) stake by 130% in Q2 2026, buying an estimated $8.44M and bringing the position to 286,986 shares worth $16.1M. The position accounts for 0.01% of the portfolio, ranked #853.

Allianz Asset Management first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. The position peaked at $21.5M in Q3 2024. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Allianz Asset Management held 286,986 shares of Royalty Pharma worth $16.1M as of Q2 2026.
  • Allianz Asset Management bought 162,080 Royalty Pharma shares in Q2 2026, an estimated $8.44M.
  • Royalty Pharma made up 0.01% of Allianz Asset Management's portfolio in Q2 2026, its #853 holding.
  • Allianz Asset Management first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • Allianz Asset Management's Royalty Pharma position peaked at $21.5M in Q3 2024.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.